USCWA
TXG icon

U.S. Capital Wealth Advisors’s 10x Genomics TXG Stock Holding History

U.S. Capital Wealth Advisors’s Portfolio TXG Stock Details TXG Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$231K Buy
+10,898
New +$218K 0.01% 901

Other funds holding TXG

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
QCM
Quantinno Capital Management New York $83.3B AUM 37.97% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $175B AUM 40.63% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.75B AUM 33.73% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

U.S. Capital Wealth Advisors's TXG Position: Q1 2026 in Review

U.S. Capital Wealth Advisors opened a new position in 10x Genomics (TXG) in Q1 2026: 10,898 shares worth $231K. The stake represents 0.01% of the portfolio and ranks #901 among its holdings.

330 funds tracked by Wall St. Rank hold TXG as of Q1 2026.

  • U.S. Capital Wealth Advisors held 10,898 shares of 10x Genomics worth $231K as of Q1 2026.
  • 10x Genomics was a new U.S. Capital Wealth Advisors position in Q1 2026.
  • 10x Genomics made up 0.01% of U.S. Capital Wealth Advisors's portfolio in Q1 2026, its #901 holding.
  • 330 funds tracked by Wall St. Rank held 10x Genomics as of Q1 2026.

Based on U.S. Capital Wealth Advisors's 13F filing for Q1 2026, filed 7 Apr 2026.